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ABSTRACT
Endoplasmic reticulum (ER) stress and unfolded protein response (UPR) are 
highly activated in cancer and involved in tumorigenesis and resistance to anti-cancer 
therapy. UPR is becoming a promising target of anti-cancer therapies. Thus, the 
identification of UPR components that are highly expressed in cancer could offer new 
therapeutic opportunity. 
In this study, we demonstrate that Endoplasmic Reticulum Metallo Protease 1 
(ERMP1) is broadly expressed in a high percentage of breast, colo-rectal, lung, and 
ovary cancers, regardless of their stage and grade. Moreover, we show that loss of 
ERMP1 expression significantly hampers proliferation, migration and invasiveness 
of cancer cells. Furthermore, we show that this protein is an important player in the 
UPR and defense against oxidative stress. ERMP1 expression is strongly affected by 
reticular stress induced by thapsigargin and other oxidative stresses. ERMP1 silencing 
during reticular stress impairs the activation of PERK, a key sensor of the UPR 
activation. Loss of ERMP1 also prevents the expression of GRP78/BiP, a UPR stress 
marker involved in the activation of the survival pathway. Finally, ERMP1 silencing 
in cells exposed to hypoxia leads to inhibition of the Nrf2-mediated anti-oxidant 
response and to reduction of accumulation of HIF-1, the master transcription factor 
instructing cells to respond to hypoxic stress. Our results suggest that ERMP1 could 
act as a molecular starter to the survival response induced by extracellular stresses. 
Moreover, they provide the rationale for the design of ERMP1-targeting drugs that 
could act by inhibiting the UPR initial adaptive response of cancer cells and impair 
cell survival.
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INTRODUCTION
The endoplasmic reticulum (ER) is a multifunctional 
organelle required for lipid biosynthesis, calcium storage, 
protein folding and processing. Proper functioning of 
ER can be affected by a variety of physiological and 
pathological parameters both inside the cell and in its 
microenvironment, as well as by different pharmacological 
agents, causing ER stress. Specific triggers of ER stress 
include hypoxia, hypoglycemia, hyperthermia, acidosis, 
calcium or redox imbalances, energy perturbation or 
fluctuations and others [1]. ER stress severely impacts 
protein folding, causing an accumulation of unfolded, 
misfolded or otherwise damaged proteins that can 
irreparably hamper cellular functions and compromise 
cell survival. Under such stress, ER evolves a group 
of signal transduction pathways, collectively termed 
unfolded protein response (UPR) [1, 2] to restore normal 
cell function by halting protein translation and activating 
the signaling pathways that lead to increased production 
of molecular chaperones involved in protein folding. 
If ER stress persists, this goal may not be achieved and 
UPR initiates apoptotic pathways to remove the stressed 
cells [1–4]. The chaperone GRP78/BiP (78 kDa glucose-
regulated protein / Immunoglobulin heavy chain binding 
protein) and CHOP (C/EBP homology protein) are the 
most prominent UPR components responsible for the 
struggle between pro-survival and pro-apoptotic modules, 
respectively. Under ER stress, GRP78/BiP dissociates 
from the three ER stress sensors, which include pancreatic 
ER kinase (PKR)-like ER kinase (PERK), activating 
transcription factor 6 (ATF6) and inositol-requiring 
enzyme 1 (IRE1), and binds to the unfolded or misfolded 
proteins. The dissociation of GRP78/BiP from these 
stress sensors allows the activation of their pro-survival 
signaling pathways [1–4].
Accumulating evidence has demonstrated that 
the ER stress and the UPR are highly induced in 
various tumors and represent important mechanisms for 
tumorigenesis and for maintaining malignancy [5]. Since 
UPR pathways remain in a quiescent state in normal cells, 
UPR is an emerging target of anti-cancer therapies. Thus, 
the identification of UPR components that are activated or 
suppressed in malignancy and the exploration of potential 
cancer therapeutics targeting the UPR are very active 
research areas [5, 6]. 
ERMP1 is a zinc-binding protease belonging to 
the peptidase M28 family [7]. In the ovary, ERMP1 
expression is required for the organization of somatic 
cells and oocytes into discrete follicular structures [8]. 
ERMP1 gene maps at chromosome 9p24, a locus recently 
described as a novel amplicon in human esophageal and 
breast cancers [9].
In this study, we identified ERMP1 as a novel 
broadly tumor-associated-antigen, with high frequency in 
breast, ovary, lung and colon cancers independently from 
cancer stages and grades. We demonstrate that ERMP1 
protein is involved in cell proliferation, migration and 
invasiveness. Moreover, we show that ERMP1 is involved 
in the activation of UPR and in the modulation of GRP78/
BiP. Finally, we show that it acts in the defense against 
oxidative stress. Overall, our results suggest that ERMP1 
could be exploited as novel molecular target for the design 
of drugs perturbing UPR. 
RESULTS
Discovery of ERMP1 over-expression in human 
cancers 
We have recently described the validation and use 
of the YOMICS@ murine polyclonal antibody library 
(http://www.yomics.com/), to discover tumor markers 
by IHC analysis [10, 11]. During the screening of the 
entire antibody library on tissue microarrays (TMAs) 
carrying cancerous and normal formalin-fixed paraffin-
embedded (FFPE) samples from breast, colon, lung, 
and ovary samples, we found that the pAb687-YOM, a 
polyclonal antibody raised against a recombinant ERMP1 
domain (amino acid 1–204) (rERMP1) specifically 
detected the expression of its target protein in cancer 
samples of the four anatomical sites whereas it gave a 
negligible staining in the corresponding normal tissues 
(Supplementary Figure S1), suggesting that ERMP1 is 
expressed at higher level in breast, colon, lung, and ovary 
cancers. A mouse monoclonal antibody (ERMP1 mAb) 
raised against rERMP1 by the conventional hybridoma 
technology and specific for rERMP1 (full details about 
the fine specificity are given below) was used to confirm 
ERMP1 expression in cancer tissues. In a first step a 
TMA carrying five duplicate tumor and the corresponding 
normal samples for each tumor type (breast, colon, lung, 
and ovary) were analyzed for their ERMP1 expression. 
ERMP1 mAb specifically stained breast (4/5 positive), 
colon (3/5 positive), ovary (4/5 positive) and lung (3/5 
positive) cancers, with a concomitant negligible staining 
in the corresponding normal samples. Afterwards, IHC 
analysis was extended to TMA carrying 43 to 47 FFPE 
samples per each tumor entity. The ERMP1 mAb showed 
positive staining in breast (94%), colon (94%), lung 
(74%), and ovary (96%) cancer samples. Most of them 
showed a moderate or strong intensity (frequencies 
ranging from 59.6 to 76.6%). In general, the staining 
was quite homogenous (50–100% of cells were stained 
by the mAb in 70% of samples) and cytoplasmic, though 
in some samples it also decorated the plasma membrane 
(Figure 1A).
The specificity of the ERMP1 mAb was verified 
by ELISA on rERMP1 (data not shown) and by Western 
blot on HeLa cells transfected with full-length ERMP1 
cDNA. As shown in Supplementary Figure S2, ERMP1 
mAb specifically detected a main band at around 300 kDa 
Oncotarget3www.impactjournals.com/oncotarget
(higher than expected) on total protein extracts of ERMP1-
transfected HeLa cells, previously separated by SDS-
PAGE under reducing conditions, which was not visible 
in HeLa cells transfected with the “empty” pcDNA3. 
1D plasmid. The high MW band was also detected by 
pAb687-YOM (Supplementary Figure S2). Though not 
investigated, the apparently aberrant ERMP1 MW could 
be ascribed to the formation of ERMP1 stable multimers 
or complexes with unknown molecule(s), which are not 
dissociated under the used conditions. To further assess 
ERMP1 over-expression in cancer, Western blot was 
carried out on total protein extracts (25 µg) of cancer and 
matched normal samples derived from cryopreserved 
surgical resections of breast (4 patients), lung (7 patients) 
and ovary (4 patients). As shown in Figure 1B, the high 
MW band, similar in size to that detected in ERMP1-
transfected HeLa cells, was clearly visible in 2/4 breast 
cancer samples, in 4/7 lung cancer samples and in 4/4 
ovary cancer samples, but not or only marginally visible 
in the corresponding normal samples.
We additionally investigated ERMP1 mRNA level 
in clinical samples from breast, lung, colon, ovary and 
prostate samples by q-RT-PCR (2 normal samples and 2-6 
tumor samples for each organ). ERMP1 transcript was 
detected in all tested samples. It was found up-regulated 
in all colon cancer and prostate cancer samples, and in 
50% of lung, ovary and breast cancer (fold increase versus 
normal samples ranging from approximately 2 to 13) 
(Supplementary Figure S3).
Finally, we investigated ERMP1 expression in 
normal tissues by IHC using a TMA carrying normal 
tissues from 33 anatomical districts (MNO961). In most 
tissues the ERMP1 mAb staining was negligible or 
negative (Supplementary Figure S4). 
Prevalence of ERMP1 in breast, lung, ovary and 
colon cancers 
To study the prevalence of ERMP1 and its potential 
clinical significance IHC analysis with ERMP1 mAb 
was performed on TMAs carrying different sets of well-
characterized FFPE samples from breast (136 cases, in 
duplicate), colon (CRC) (667 cases), lung (368 cases of 
Non-Small-Cell Lung Carcinoma (NSCLC) and ovary 
(150 cases) cancers, selected on the basis of the availability 
of relevant clinical and molecular data (Supplementary 
Table S1). In general, the staining was quite homogenous 
and predominantly cytoplasmic with sporadic accentuation 
on plasma membrane.
In breast cancer, ERMP1 was detected in 94.2% of 
the cases, 42.3% showed a strong or moderate staining 
(see Materials and Methods). An analysis stratified on 
available clinico-pathological data (Table 1) showed that 
the frequency of the protein expression was independent 
from tumor stage, histological grading and hormonal 
receptors as well as HER2 status (Table 1). Interestingly, 
ERMP1 showed a high/moderate staining in 57% of the 
triple negative (HER2-, ER-, PR- negative) breast cancer 
samples (Table 1).
In CRC, ERMP1 was detected in 97.9% of the 
cases, 80.7% showed a strong or moderate staining. Also 
in this cancer type, the protein expression was found 
to be independent from pT and pN stages (Table 1). In 
CRC ERMP1 expression was also independent from the 
mutational state of the V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog (KRAS) and v-Raf murine sarcoma 
viral oncogene homolog B (BRAF) genes. Detailed 
information regarding KRAS and BRAF analysis of tumor 
samples are summarized in Supplementary Table S1. 
In NSCLC cancer, ERMP1 was detected in 95.4% 
of the cases, 41.4% of which showed a strong or moderate 
staining. Also in this cancer type, no association was 
found between protein expression levels and pathological 
features including grading and proliferation index as 
assessed by Ki67 immunostaining (Table 1).
In ovarian cancer, ERMP1 was detected in 96.7% 
of the samples, with a strong to moderate staining in 
35.3% of them and without association with pT stages 
(Supplementary Table S1). 
ERMP1 is expressed intracellularly in cancer cell 
lines 
IHC data showed that ERMP1 is highly expressed 
in breast, colon, lung and ovary cancers. Therefore we 
assessed ERMP1 expression in a panel of cell lines derived 
from these tumors by Western blot using the ERMP1 mAb. 
Among the cell lines tested, the high MW ERMP1 band 
was detected in 9 cell lines including the breast cell lines 
SK-BR-3 and MCF7, the lung cell line H226, the colon 
cell lines Colo205, HCT116 and HCC2998, and the ovary 
cell lines OVCAR3 OVCAR4 and OVCAR8 (Figure 2A) 
whereas the same band was absent or weak in the other 
tested cell lines. The specificity of the immune-reactive 
band was further confirmed by gene silencing using the 
RNA interference technology. SK-BR-3 and MCF7 cells 
were transfected with four different ERMP1-specific 
siRNAs or with a scrambled siRNA and 72 hours later 
the reduction of ERMP1 mRNA level was assessed by 
q-RT-PCR. Transfection with 10 nM or 50 nM of ERMP1 
siRNAs caused a substantial loss of cell adherence and 
viability (see paragraph below). When used at 1nM, 
ERMP1 mRNA was significantly reduced at similar level 
by the four ERMP1 specific siRNAs (Supplementary 
Figure S5). Western blot analysis of total cell lysates 72 
and 96 hours after transfection of siRNA showed that 
ERMP1 silencing markedly reduced the ERMP1 immuno-
reactive band (Figure 2B). A similar effect was obtained 
with all tested siRNAs (data not shown). 
We then assessed ERMP1 localization by 
immunostaining and confocal microscopy analysis 
of selected cancer cell lines previously found to be 
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ERMP1 positive by Western blot. Figure 2C shows 
that in MCF7, SK-BR-3 and OVCAR8 cells, the 
ERMP1 protein is localized intracellularly and it 
partially accumulates in the perinuclear region. 
Similar localization results were obtained in HeLa 
cells transfected with ERMP1 cDNA, run in parallel as 
control. This result is in agreement with its annotation 
of protein associated to the ER [8].
Table 1: Frequency of ERMP1-positive cancer samples
ERMP1 positive ERMP1 moderate or high intensity 
CANCER Parameter Scoring N° of samples
N° of 
samples % N° of samples %
BREAST pT 1&2 110 106 96.4 49 44.5
3&4 23 20 87.0 7 30.4
pN 0&1 107 101 94.4 48 44.9
2&3 12 12 100.0 3 25.0
Grade 1&2 74 69 93.2 30 40.5
3 63 60 95.2 28 44.4
Her2 + 15 14 93.3 4 26.7
– 121 113 93.4 54 44.6
ER + 97 92 94.8 39 40.2
– 39 36 92.3 19 48.7
PR + 34 31 91.2 15 44.1
– 89 84 94.4 39 43.8
Receptor 
profile
Her2+ER+PR+ 1 1 0
Her2+ER+PR– 5 5 2
Her2+ER–PR– 6 5 1
Her2–ER+PR+ 33 30 90.9 15 45.5
Her2–ER+PR– 50 48 96.0 20 40.0
Her2–ER–PR– 28 26 92.9 16 57.1
COLON pT 1&2 132 131 99.2 111 84.1
3&4 513 508 99.0 415 80.9
pN 0&1 511 503 98.4 420 82.2
2 137 131 95.6 103 75.2
Grade 1&2 613 600 97.9 493 80.4
3 39 38 97.4 33 84.6
K-RAS Wt 180 175 97.2 152 84.4
Mut 84 83 98.8 70 83.3
B-RAF Wt 230 225 97.8 193 83.9
Mut 24 23 95.8 18 75.0
LUNG pT 1&2 368 351 95.4 153 41.6
Grade 1&2 198 187 94.4 85 42.9
3&4 158 153 96.8 63 39.9
Ki67 0&1 144 137 95.1 72 50.0
2&3 202 194 96.0 81 40.1
OVARY pT 1&2 20 18 90.0 6 30.0
3 123 120 97.6 45 36.6
Staining frequency was not calculated for groups with less than 10 samples.
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Figure 1: ERMP1 is over-expressed in breast, lung, colon and ovary cancers. (A) Immunostaining of cancerous and normal 
samples with the anti-ERMP1 mAb. (B) Immunoblot analysis of clinical samples. Total protein extracts (25 μg) from cryo-preserved breast, 
lung and ovary biopsies of cancer (K) and normal (N) tissues from patients were separated by SDS-PAGE and subjected to Western blot 
with anti-ERMP1 or anti-actin mAbs. Total extracts from HeLa cells transfected with ERMP1 coding plasmid and mock-transfected (empty 
plasmid) cells were analyzed in parallel as controls. Molecular weight markers (MW) are on the right. 
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ERMP1 depletion reduces cell proliferation and 
invasiveness of cancer cell lines, but it does not 
influence apoptosis
We then investigated the role of ERMP1 in processes 
important for tumor development, such as proliferation, 
apoptosis and invasiveness, by gene silencing of SK-BR-3 
and MCF7 cell lines with ERMP1-siRNAs or scramble 
siRNAs (1 nM). Proliferation analysis was assessed by 
the MTT assay on siRNA-treated cells cultured either in 
serum-free medium (starvation medium), or added with 
2.5% FCS, with our without 10 ng/ml EGF as proliferative 
stimuli and analyzed by the MTT assay. A 2-fold reduction 
of cell proliferation was observed in all tested culture 
conditions (Figure 2D) subsequent to ERMP1 silencing. 
Cell invasiveness was then assessed in vitro by 
the Boyden assay. ERMP1-silencing induced a marked 
reduction of the invasive phenotype of both cell lines, 
compared to control samples (Figure 2E). Moreover, 
the effect of ERMP1 in apoptosis was assessed by the 
Annexin V- PI staining. ERMP1 silencing did not alter the 
percentage of apoptotic cells (data not shown). 
Since ERMP1 is involved in the cellular response 
to hypoxia, as described in the following paragraphs, 
the effect of ERMP1 silencing on cell proliferation 
was assessed in MCF7 and SK-BR-3 cells cultured for 
24 hours in hypoxic conditions (1% O
2
), as compared to 
cells maintained in normoxia (20% O
2
). The inhibition of 
cell proliferation caused by loss of ERMP1 was similar 
in hypoxia and normoxia (Supplementary Figure S6), 
indicating that the ERMP1 role in cell proliferation is 
independent from oxygen availability. 
ERMP1 expression is modulated by endoplasmic 
reticulum and reactive oxygen species oxidative 
stresses
The identification of the regulatory or environmental 
conditions that promote ERMP1 expression could 
contribute to elucidate its role in cancer cells. To this 
purpose, we exposed MCF7 and SK-BR-3 cells to a series 
of stimuli that induce structural and metabolic cell changes 
and monitored ERMP1 expression, as compared to cells 
grown in standard conditions. Cells were either grown 
for 24 hours under hypoxia (1% O
2
), ER stress (0.5 µM 
thapsigargin) or reactive oxygen species stress (3 µM 
menadione) or acidic stress (pH 6.8). In parallel, to mimic 
the effect of tumor microenvironment, cancer cells were 
also co-incubated for 24 hours with the conditioned media 
(CM) from stromal cells known to be involved in cancer 
progression, such as cancer-associated fibroblasts (CAFs). 
Western blot analysis of total cell extracts showed in 
Figure 3 indicates that exposure to hypoxia, thapsigargin 
and menadione significantly decreased ERMP1 expression 
in both cell lines, with thapsigargin causing the most 
marked effect. Cell exposure to CM-CAFs decreased 
ERMP1 expression only in SK-BR-3 cells. Acidic stress 
did not alter ERMP1 expression. ERMP1 transcription 
analysis in MCF7 and SK-BR-3 cells under hypoxia, 
thapsigargin and menadione by q-RT-PCR did not show 
any significant alteration of ERMP1 transcript level, as 
compared to untreated cells (data not shown).
ERMP1 is involved in the UPR and the response 
to oxidative stress
The effect of thapsigargin, menadione and hypoxia 
on ERMP1 expression in cancer cells led to the hypothesis 
that ERMP1 is involved in the UPR and in the response 
to oxidative stress. We addressed ERMP1 role in UPR 
by ERMP1 silencing in SK-BR-3 and MCF7 cells, and 
monitoring the activation of PERK, inferred by the 
accumulation of the phosphorylated form of the protein, 
and the expression of GRP78/BiP, two fundamental 
UPR mediators. We found that ERMP1 knock-down 
inhibits PERK phosphorylation, as judged by Western 
blot analysis of protein cell extracts using antibodies 
able to discriminate the PERK phosphorylated and non-
phosphorylated forms (Figure 4A). Moreover, ERMP1 
knock-down reduces GRP78/BiP transcription level, as 
judged by q-RT-PCR analysis of total RNA purified from 
the cell samples (Figure 4B), thus confirming that ERMP1 
is involved in the activation of the signaling pathway 
responsible for ER homeostasis.
In order to investigate the ERMP1 role in the 
response to oxidative stress, we assessed the expression 
of the nuclear factor-E2-related factor-2 (Nrf-2) and the 
hypoxia inducible factor 1 (HIF-1), two master effectors 
of oxidative stress response, in SK-BR-3 and MCF7 
cells treated with ERMP1 siRNAs and maintained for 
24 hours in normoxia (20% O
2
) or hypoxia. We found that 
ERMP1 knockdown significantly decreases the expression 
of HIF- 1 protein levels (Figure 5A) under both O
2
 
conditions. In contrast, Nrf2 expression was significantly 
reduced under hypoxia, while it changed only marginally 
under normoxia. An analysis of the intracellular level of 
reactive oxygen species (ROS) in these samples using the 
DCFDA assay showed a marked increase of ROS both 
at 20% O
2
 and 1% O
2
, compared to their non-silenced 
counterparts (Figure 5B).
DISCUSSION
ERMP1 gene (alias FxnA and KIAA1815) 
encodes a metallopeptidase belonging to the M28 
family of approximately 100 kDa, with nine predicted 
transmembrane domains normally localized in the ER. 
In the rat ERMP1 gene is expressed in granulosa cells 
and its abundance is maximal 48 hours after birth, i.e. 
during the initiation of follicular assembly [8]. Rat 
ERMP1 is required for the organization of somatic cells 
and oocytes into discrete follicular structures, since 
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Figure 2: ERMP1 is expressed in human cancer cell lines and is involved in cell proliferation and invasiveness. (A) ERMP1 
expression in cancer cells lines. Total extracts of the indicated cancer cell lines were separated on SDS-PAGE (25 μg/lane, corresponding 
to approximately 0.5 × 106 cells) and subjected to Western blot using the anti-ERMP1 mAb. Total extracts from HeLa cells transfected 
with ERMP1 coding plasmid and mock-transfected (empty plasmid) cells were analyzed in parallel as controls. Images derive from distinct 
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loss of ERMP1 causes substantial loss of follicles, 
and structural disorganization of the ovary, with many 
abnormal follicles containing more than one oocyte and 
clusters of somatic cells not associated with any oocytes. 
ERMP1 role in the follicular organization seems to be 
ascribed to its proteolytic activity on precursor proteins 
required for intra-ovarian cell-to-cell communication 
[8]. Studies in human esophageal and breast cancers 
showed that ERMP1 gene is located in the 9p24 genomic 
amplicon. In breast cancer the 9p24 genomic amplicon 
contains six genes, among which ERMP1 and IL33 are 
overexpressed independently of the copy number increase, 
while GASC1, UHRF2, KIAA1432 and C9orf123 are 
overexpressed only in the context of gene amplification 
[9]. Accumulating evidences support the notion that the 
9p24 amplicon contains candidate oncogenes. Indeed, 
GASC1 and UHRF2 encodes epigenetic factors involved 
in tumorigenesis [9,12–15]. Concerning ERMP1, its role 
in cancer was so far unknown.
The present study brings a substantial contribution 
to our current knowledge on ERMP1 and provides robust 
experimental evidence of its association with cancers 
with high morbidity and mortality rate. By an extensive 
IHC investigation we discovered that the protein is highly 
expressed in a large fraction of breast, colon, lung, and 
ovary cancers (frequency ranging from approximately 
94% to 98%), among which, the highest expression level 
(as judged by samples with strong/moderate IHC staining 
intensity) was found in colon cancer (80.7%), compared 
to lung, breast cancer and ovary cancer (41.4%, 42.3%, 
immunoblots. (B) ERMP1 knockdown by siRNA. MCF7 and SK-BR-3 cells were transfected with 1nM of ERMP1-specific siRNAs or 
scramble controls. After 72 and 96 hours, total protein extracts were separated by SDS-PAGE, blotted on nitrocellulose membranes and 
subjected to Western blot using the anti-ERMP1 mAb, and an anti-actin antibody as internal control. (C) ERMP1 localization in cancer cells 
lines. Confocal microscopy analysis of cells fixed, permeabilized and incubated with the anti-ERMP1 mAb. HeLa cells transfected with 
ERMP1 coding plasmid and mock control cells were analyzed in parallel. Cells were stained with Alexafluor 488-labeled goat anti-mouse 
antibodies to detect ERMP1 (green) and DAPI to visualize nuclei (blue). (D) Cell proliferation. MCF7 and SK-BR-3 cells were transfected 
with ERMP1-specific or scrambled siRNA. After 48 hours cells (2 × 104 /well) were plated in 96 well plates and incubated for additional 
24 hours in medium containing 2.5% FBS, with or without 10ng/ml EGF or in stimuli-free medium. Thereafter proliferation was assessed 
by the MTT assay. (E) Cell invasiveness. MCF7 and SK-BR-3 cells transfected with ERMP1-specific siRNA or scrambled siRNA were 
loaded of matrigel-coated 96-well plates and analyzed by the Boyden invasion assay. Cells migrated towards the lower surface of the 
chamber filters were fixed and counted after Diff-Quick staining. Images of the visual counting of each sample are reported below the 
graphs. Asterisks mark samples showing a significant difference (**p < 0.05; ***p < 0.01). (F) Reduction of ERMP1 transcript level 
in MCF7 and SK-BR-3 cells upon gene silencing. q-RT-PCR was performed using MAPK gene as housekeeping control. Data from 
phenotypic assays represent the means of three replicated experiments, run in triplicate.
Figure 3: ERMP1 expression is modulated by tumor microenvironment stimuli. Western blot analysis of ERMP1 expression in 
response to oxygen availability, pH and oxidative stresses. MCF7 (left) and SK-BR-3 cells (right) were cultured for 24 h under hypoxia (1% 
O
2
), 0.5 µM thapsigargin (TG), 3 µM (MN) menadione, acidic medium (pH 6.8), or with conditioned media (CM) from cancer-associated 
fibroblasts (CAFs). Total cells extracts were separated by SDS-PAGE (25 µg/lane) and analyzed by Western blot with the anti-ERMP1 and 
actin-antibodies. Graphs below the immunoblots represent a relative quantification of ERMP1, expressed as chemiluminescence intensity 
ratio of ERMP1 vs actin bands. Data represent the mean values of four replicated experiments (**p < 0.05 and ***p < 0.01).
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Figure 4: ERMP1 controls the ER stress-induced activation of PERK and GRP78/BiP. (A) Western blot analysis of PERK 
phosphorylation in response to ERMP1 silencing and thapsigargin stress. MCF7 and SK-BR-3 cells knocked down for ERMP1 gene or 
non-silenced (scrambled siRNA) were treated with 0.5 µM thapsigargin (TG) for 24 hours in starvation medium, lysed, and cell lysate were 
separated by PAGE-SDS and used for Western Blot analysis. The membranes were treated with anti-ERMP1, anti-p-PERK, anti-PERK 
and anti-actin antibodies. (B) q-RT-PCR analysis of GRP78/BiP transcription in MCF7 and SK-BR-3 cells subsequent to ERMP1-silencing 
and/or exposition to thapsigargin stress. Total RNA was isolated from the MCF7 and SK-BR-3 the same cell samples and GRP78/BiP 
transcription was analyzed by q-RT-PCR, using β2-microglobulin as reference gene for sample normalization. Data are expressed as means 
± S.D. calculated on an average of four independent experiments (**p < 0.05 and ***p < 0.01).
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Figure 5: ERMP1 contributes to the cellular response to oxidative stress. (A) Western blot analysis of ERMP1 HIF-1, and 
Nrf2 in response to ERMP1 silencing and oxygen availability. MCF7 and SK-BR-3 cells (left and right, respectively) knocked down for 
ERMP1 gene or non-silenced were cultured for 24 hours at 20% O
2
 and at 1% O
2
, and cell extracts were used for Western Blot analysis 
with anti-ERMP1, anti-HIF-1, anti-Nrf2 and anti-actin antibodies. Graphs below each immunoblot represent the relative quantification 
of the ERMP1, HIF-1, and Nrf2 expression vs actin, obtained by averaging chemiluminescence band intensity data, representative of 5 
independent experiments. (B) ERMP1 silencing causes accumulation of intracellular ROS. The level of intracellular ROS in ERMP1-
silenced MCF7 and SK-BR-3 cells cultured at 20% O
2
 and 1% O
2 
was evaluated with DCFDA. Data are expressed as means ± S.D. 
calculated on an average of four independent experiments (*p < 0.1; **p < 0.05 and ***p < 0.01).
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35.3% and respectively). In accordance, ERMP1 transcript 
was found upregulated in these cancer types. A prevalence 
analysis in these four tumor types showed that ERMP1 
is expressed at similar level in early and late stages 
as well as in highly and poorly differentiated cancers. 
Interestingly ERMP1 expression seems to be independent 
from important predictive biomarkers in breast as well as 
in colon cancer. In breast cancer, ERMP1 is expressed at 
similar frequency regardless of the expression of HER2, 
progesterone and estrogen receptors. Importantly, it 
is expressed in a significant fraction of triple negative 
breast cancer samples (93% positivity, 57% of which with 
moderate or high intensity). In colon cancer, ERMP1 is 
expressed irrespective of KRAS and /or BRAF mutational 
status. Although not deeply investigated, our q-RT-PCR 
data indicate that ERMP1 is also upregulated in prostate 
cancer. Moreover, public transcriptome results available 
at the Oncomine database (https://www.oncomine.org), 
score ERMP1 among the top 10% over-expressed genes in 
breast and liver cancer (data from 5 and 2 studies related 
to cancer-versus-normal comparisons, respectively). 
In agreement with its predicted localization we 
found ERMP1 in the intracellular compartment of cancer 
cells by IHC and confocal microscopy. ERMP1 migrates 
in SDS-PAGE with an unexpected MW of approximately 
300 kDa, suggesting that it could form stable 
homomultimers or complexes with unknown molecule(s), 
which are not dissociated under the denaturing and 
reducing conditions used in Western blot.
The evidence that ERMP1 is a broadly and highly 
expressed in several cancer types suggests that it plays 
an important role in cell processes and pathways crucial 
for cancer development. Our in vitro studies strongly 
support this hypothesis and indicate that ERMP1 acts 
as an important player in ER stress and UPR, as well as 
in the defense against oxidative stress. Although a full 
understanding of ERMP1 function in the UPR pathway 
and in the defense to oxidative stress would deserve more 
in-depth studies, our working hypothesis is that ERMP1 
contributes as a molecular starter to the survival response 
induced by extracellular stresses. This hypothesis is 
based on five major observations. First, loss of ERMP1 
expression caused by transient ERMP1 silencing 
significantly affects proliferation and invasiveness of 
ERMP1-positive cancer cells, suggesting a role of the 
protein in growth and propagation of cancer cells. We 
measured such effect only in vitro, since we could not 
obtain stable ERMP1 knock down, likely due to low cell 
viability.
Second, ERMP1 expression is affected by 
menadione- and thapsigargin-induced stresses, and 
by hypoxia stimuli mimicking conditions typically 
encountered by cancer cells in their natural environment, 
which are acknowledged stimuli of UPR. Third, loss of 
ERMP1 expression during thapsigargin stress significantly 
decreases the level of PERK activation/phosphorylation 
and the expression of the stress marker GRP78/BiP, 
thereby suggesting an impairment of UPR activation. 
Upon stress sensing, tumor cells activate UPR and 
GRP78/BiP, which initiate the cyto-protective aspects 
and promote the ability of cancer cells to survive the 
hostile microenvironment. Fourth, ERMP1 silencing in 
cells exposed to 1% O
2
 hypoxia, a stimulus associated to 
mitochondrial delivery of oxidants and hence sustaining 
oxidative stress, leads to inhibition of the Nrf2-mediated 
anti-oxidant response. Under ER stress, the PERK/Nrf2 
signaling pathway coordinates the interplay between 
UPR and oxidative stress caused by the accumulation 
of ROS. NrF2, a direct phosphorylation substrate of 
activated PERK, migrates to the nucleus to activate gene 
encoding anti-oxidant proteins and detoxifying enzymes, 
fighting perturbations in redox homeostasis [16, 17]. 
Fifth, ERMP1 silencing under hypoxia leads to reduction 
of accumulation of HIF-1, the master transcription factor 
instructing cells to respond to hypoxic stress. Hypoxia, a 
common feature of several solid advanced cancers, has 
been associated with both UPR and oxidative stress due 
to mitochondria deregulation [18, 19]. Such stimulus 
activates both UPR via the PERK downstream pathway 
and the HIF-s pathway [20]. These findings suggest that 
ERMP1 is involved in the ability of cancer cells to respond 
to hypoxia as a stress and oxidative signal, indicating that 
both HIF-1 and Nrf2 transcription factors are affected 
by ERMP1 RNA interference. In keeping with this idea, 
hypoxic and oxidative signals are often common in 
aggressive cancers, they trigger joint molecular pathways 
and converge on HIF-1 as a central player [21–23]. 
Indeed, HIF-1 transcription factor is a redox-sensitive 
protein, due to its regulation by a Fe-dependent prolyl 
hydroxylase that, upon ROS-mediated inactivation leads 
to HIF-1 stabilization. It is therefore likely that EMRP1, 
mediating UPR in cancer cells, acts upstream to both 
hypoxic and oxidative stress signals, thus behaving as a 
central molecular hub in stressful circumstances.
An unsolved question is why ERMP1 protein 
expression level decreases under ER stresses that activate 
UPR, whereas its transcriptional level remains unaltered. 
Although not investigated, this phenomenon might be 
explained by an altered turnover of the protein caused by 
PERK activation. Indeed, under ER stress, the eukaryotic 
initiation factor 2 alpha (eIF2𝛼) is phosphorylated by 
PERK and it inhibits global protein synthesis while 
preserving a selective translation of a small number 
of mRNAs involved in UPR, including the activating 
transcription factor 4 (ATF4) [1, 5]. Under this condition, 
ERMP1 could be rapidly consumed in the attempt to 
re-establish ER normal state but its expression level is 
not restored, as a consequence of eIF2𝛼 –P-mediated 
attenuation of protein translation. 
Overall, our study highlights ERMP1 as a novel 
target for anti-cancer therapies. Since the protein is 
localized intracellularly, it is amenable to the development 
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of nanocarrier-based approaches able to drive ERMP1-
specific silencing tools within the cells [24, 25]. Moreover, 
its involvement in UPR could foster the development 
of novel drugs targeting UPR. Anti-cancer approaches 
affecting the UPR pathway are having initial successes in 
clinical studies [1, 5]. The therapeutic potential of drugs 
targeting the UPR components in cancer mainly involves 
two approaches, both promoting cell deaths: induction of 
accumulation of misfolded protein in ER to overload the 
unfolded protein response so as to induce the pro-apoptotic 
pathways or inhibition of UPR adaptive response and 
pro-survival pathway. Our data provide the rationale for 
the design of novel ERMP1-targeting drugs that could 
act by inhibiting the UPR initial adaptive response of 
cancer cells and impair cell survival. Moreover, since 
high expression of GRP78/BiP protect cancer cells from 
the cytotoxic effects of several chemotherapeutic agents 
[26, 27], targeting ERMP1 could also weaken GRP78/BiP-
dependent chemoresistance mechanisms of cancer cells.
A concern that may limit the exploitation of UPR 
in anti-cancer therapy is that most components of this 
pathway can be activated by a variety of physiological and 
pathological conditions, not necessarily related to cancer, 
as well as by different pharmacological agents [1]. Thus, 
the use of drugs affecting UPR may lead to unwanted 
toxic effects in non-cancerous cells suffering from various 
stresses. In this context ERMP1, being highly expressed in 
cancer cells might be used to overcome the current limit of 
UPR targeting drugs.
MATERIALS AND METHODS
Reagents, cell cultures and TMAs
Unless specified, all reagents were obtained from 
Sigma. His-tagged recombinant ERMP1 domains were 
generated in E. coli as described [10]. Human cells were 
obtained from the ATCC collection and, unless differently 
stated, cultured under ATCC recommended conditions. 
Anti-HIF-1 antibody was from BD Transduction 
Laboratories. Anti-Nrf2, anti-actin and anti-p-PERK 
antibodies were from Santa Cruz Biotechnology. Anti-
PERK antibody was from Cell Signaling Technology. The 
four TMAs used were produced within previous Biobank 
activities at Pathology of the University Hospital of Basel. 
All activities were conducted previous acquirement of the 
local ethical committee permission. A commercial TMA 
(MNO961, Pantomics, Richmond, CA, USA) carrying 
normal samples from 33 organs was also used to assess 
ERMP1 staining.
IHC analysis 
For each cancer entity different histological stages 
and grades are represented except for NSCLC where 
all samples were diagnosed as pT1 or pT2, and pN0 
(Supplementary Table S1). TMA production and IHC 
staining were performed essentially as previously described 
[11, 28, 29]. Briefly, formalin-fixed, paraffin-embedded 
tissue blocks of surgical resections were retrieved from 
the archives of the Institute of Pathology, University 
Hospital Basel and the Institute of Clinical Pathology 
Basel, Switzerland. Cancer and normal samples were 
arrayed in parallel on the same TMA slides and analyzed 
simultaneously. One tissue cylinder with a diameter of 
0.6 mm was punched from morphologically representative 
tissue areas, mostly central tumor areas and rather away 
from the infiltrating tumor border. Clinico-pathologic 
data from the corresponding series of cancer cases were 
obtained from archived files. In breast cancer tissue, 
positivity to human epidermal growth factor receptor 
2 (HER2), progesterone and estrogen receptor were 
annotated as previously described [30]. Briefly ER and PR 
staining was scored semiquantitatively using the proportion 
of positive tumor cells over total tumor cells (%-positivity, 
ranging from 0% to 100% at 5% intervals). Any intensity of 
staining of more than 10% was considered positive. FISH 
analysis was used to detect the amplification of HER2. A 
tumor was considered amplified if the ratio of oncogene ⁄ 
centromere was ≥ 2.0. In lung cancer, positivity to Ki67 
was also scored semiquantitatively using the proportion of 
positive tumor cells over total tumor cells (%-positivity, 
ranging from 0% to 100% at 5% intervals). In CRC, 
Sanger sequencing analysis for BRAF and K-RAS gene 
alterations, was performed as previously described [31].
Concerning the scoring of ERMP1 staining slides 
were screened semiquantitavely for the percentage and 
the intensity of the signal for ERMP1. At least 100 cells 
were counted for each punch. Intensity of the signal was 
graded semiquantitavely in 4 groups from 0 (no positivity) 
to 3 (strong positivity). A case was considered low positive 
if showed a positive signal between 10% and 33% of 
cells, moderate positive between 33 and 66% and strong 
positive more than 66%. Negative control samples were 
prepared by using an irrelevant isotype control antibody 
and/or by omitting the primary antibody. The study was 
approved by the Human Research Ethic Committee of 
University Hospital of Basel (Ethikkommission Nord-und 
Zentralschweiz, reference number EK 322/13). 
Cell transfection
A pcDNA3.1D (Invitrogen) derivative plasmid 
encoding ERMP1 full length cDNA was generated and 
sequence verified. Transfection was assessed in HeLa cells 
using a protocol already described [10]. 
Environmental stimuli
The influence of oxidative stress on ERMP1 
expression was assessed in SK-BR-3 and MCF7 cells 
using DME medium without sodium bicarbonate 
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supplemented with 25 mM HEPES, 10 mM sodium 
bicarbonate supplemented with 3µM menadione, or 0.5 µM 
thapsigargin, or brought to pH 6.8 (acidic pH stress). 
Moreover the influence of CAFs conditioned medium 
was tested. To obtain CAFs conditioned medium, human 
mammary fibroblasts were grown to sub-confluence, treated 
for 24 hours with 10 ng/ml transforming growth factor 
β (TGF-β) (Peprotech) and then starved for additional 
24 hours before collecting the conditioned medium. 
ERMP1 silencing 
ERMP1 was silenced in the indicated cancer 
cell lines with suboptimal concentrations (1 nM) of 
4 commercially available ERMP1-specific siRNAs 
(#SI04291497, #SI03226006, #SI03132311, #SI00460873, 
QIAGEN) or irrelevant siRNA (AllStars Negative Control 
siRNA, QIAGEN) using the HiPerfect transfection reagent 
(QIAGEN) following the manufacturer’s protocol. Loss 
of ERMP1 expression was verified by q-RT-PCR and WB 
(after 48 or 72 hours). 
Electrophoresis and western blot analysis
Cells were suspended in Laemmli electrophoresis 
buffer (without β-mercaptoethanol and bromophenol blue) 
and assayed for protein content by the bicinchoninic acid 
(BCA) and the Bradford method. After that each sample 
were additioned with β-mercaptoethanol and separated by 
SDS-PAGE. Subsequently gels were electroblotted onto 
Polyvinylidene difluoride (PVDF) membranes (Millipore) 
and the blots were incubated with anti-ERMP1, anti-Nrf2, 
anti-Actin, anti-HIF-1, anti-PERK and anti-p-PERK. After 
incubation with secondary antibodies, the blotting was 
developed by using the ECL plus immunodetection system 
(Bio-Rad) and the chemiluminescence was visualized 
by UVP (Ultra-Violet Products) Ltd Chemidoc-it 500 
Imaging System. Quantitative analysis of the spots was 
carried out by Kodak MI software.
RNA extraction and q-RT-PCR analysis
RNA extraction from clinical samples and cell lines 
was performed using the RNeasy mini kit (QIAGEN) and 
500 ng of it were reverse transcribed using Superscript 
III Reverse Transcriptase (Life Technologies) with oligo 
dT. Triplicate cDNA samples from each cell line (equal 
to 50 ng RNA/sample) were subjected to real-time q-PCR 
to assess the relative ERMP1 (Quantitect® Primer Assay 
for Human ERMP1, QIAGEN) and GRP78/BiP (primers: 
5′-CGTGGATGACCCGTCTGTG-3′ and 5′-CGTCTTT 
GGTTGCTTGGC-3′) transcript levels using the Quantitect® 
SYBR Green PCR kit (QIAGEN). MAPK, actin (Quantitect® 
Primer Assay for Human actin or MAPK, QIAGEN), 
or β2-microglobulin (primers: 5′-AGTATGCCTGCC 
GTGTGAAC-3′ and 5′-GCGGCATCTTCAAACCTC 
CA-3′) were used as an internal normalization controls, 
respectively. Data were analyzed with the One-Step Plus 
q-RT-PCR equipment (Applied Biosystems). 
Measurement of intracellular ROS
Cells were cultured for 24 hours in starvation 
medium at 20% O
2
 and at 1% O
2
, after that cells were 
treated with 5 µg/mL of 2′,7′–dichlorofluorescin diacetate 
(DCFDA) for 15 minutes, washed with PBS and lysed in 
RIPA buffer. The fluorescence was immediately detected 
by spectrophotometric analysis at 510 nm.
Confocal microscopy
Cells were plated on microscope coverslips, stained 
with the anti-ERMP1 antibodies at the appropriate 
concentrations, using a previously described protocol [11]. 
For detection, Alexafluor 488-labeled goat anti-mouse 
antibodies and DAPI were used.
Phenotypic assays
Cell viability and apoptosis were measured by the 
MTT (Promega) and the Annexin V-PI assays (Sigma). 
Assays were performed in 96w-well plates according to 
the manufacturer’s instruction. Cell invasiveness was 
assessed by the Boyden chamber assay. The indicated 
cell lines (2000/well) were placed into 24-well plates 
containing 500 μl of DMEM complete medium. After 
ON incubation at 37°C, non-invading cells were removed 
mechanically using cotton swabs, and micro-porous 
membrane containing the invaded cells was fixed in 96% 
methanol and stained with Diff-Quick staining solutions. 
Invasiveness was evaluated by counting the cells that 
migrated towards the lower surface of the filters (10 
randomly chosen fields for each filter). Each experiments 
was carried out in triplicate and averaged from at least 3 
independent experiments.
Statistical analysis
Statistical analysis of the phenotypic data was 
performed using two-tailed Student’s t-test. The statistical 
association between the clinico-pathological variables and 
ERMP1 IHC staining was assessed with the chi-square 
test. P-values ≤ 0.05 were considered significant. 
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